Crux Biolabs, a leading Australian laboratory for vaccines, immunotherapies, immuno-oncology and infectious diseases, has announced a significant investment of growth capital by healthcare specialist investor Genesis Capital.

The investment will drive a new phase of growth for company, allowing Crux to quickly expand in line with the global demand for Australian high-quality pre-clinical and clinical testing.

Based in Melbourne, Crux Biolabs is known for its specialized immunology services, to help understand why cutting-edge cancer therapies work for some patients but not others. Crux works closely with pharmaceutical sponsors, CROs and academic institutions globally in support of their growing clinical trial needs in Australia. Genesis invests to join existing shareholder Leading Technology Group who will remain as a shareholder.

The investment from Genesis will fast-track expansion for Crux, with a focus of capital into the business enabling an increasing in the breadth and volume of testing offered to the market.

Genesis Capital invested an undisclosed amount in Crux Biolabs for a majority stake, with Leading Technology Group retaining a shareholding position in the business.